Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

Core Insights - Dyne Therapeutics plans to announce topline clinical results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER trial for zeleciment rostudirsen on December 8, 2025 [1] - A webcast will be hosted at 8:00 a.m. ET to discuss the results, with a press release issued prior to the event [1][2] Company Overview - Dyne Therapeutics focuses on delivering functional improvement for individuals with genetically driven neuromuscular diseases [3] - The company is developing therapeutics targeting muscle and the central nervous system to address the root causes of diseases [3] - Current clinical programs include myotonic dystrophy type 1 and Duchenne muscular dystrophy, with preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease [3]